Aerpio Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

CINCINNATI--()--Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that President and CEO Joseph Gardner, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 3:30 p.m. Eastern Time at the Boston Marriott Copley Place. Dr. Gardner will provide a corporate overview and business update, including anticipated milestones for 2016, and will also be available to participate in one-on-one meetings with registered attendees.

About Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of vascular disorders with an emphasis on diseases of the eye. Aerpio is a leader in the development of therapeutics based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class small molecule stabilizer of the Tie2 pathway and is in clinical development for diabetic retinopathy. More information is available at www.aerpio.com.

Contacts

Aerpio Therapeutics, Inc.
Dhaval Desai
Vice President of Medical Affairs
ddesai@aerpio.com
or
Burns McClellan on behalf of Aerpio Therapeutics
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Contacts

Aerpio Therapeutics, Inc.
Dhaval Desai
Vice President of Medical Affairs
ddesai@aerpio.com
or
Burns McClellan on behalf of Aerpio Therapeutics
Justin Jackson, 212-213-0006
jjackson@burnsmc.com